Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cook CE marks Zilver PTX

This article was originally published in Clinica

Executive Summary

Cook Medical has CE marked its Zilver PTX paclitaxel-eluting stent for sale in Europe. The polymer-free device is designed for use in peripheral artery disease (PAD); specifically, to treat severe blockages in the superficial femoral artery. The self-expanding stent, made of Nitinol, was implanted in patients for the first time on August 10. PAD is estimated to affect 27 million individuals in Europe and North America, three quarters of whom are asymptomatic. The stent is not yet approved for sale in the US.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044045

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel